Closing
Do PCSK9 inhibitors improve inflammation & biomarkers versus placebo?
Mostly studied in coronary & atherosclerotic disease.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Doubtful. So far, no trial evidence yet.
NoUnsureYes
- Belief
- 0.25 (range 0.10–0.70)
- Trials for
- 0
- Trials against
- 0
- Inconclusive
- 3
Already under way
- PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS): Study Protocol for a Multicenter Randomized…NCT06791031 · not yet recruiting · started 2026
- PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary PreventionNCT07581808 · recruiting · started 2026
- Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)NCT06730802 · not yet recruiting · started 2025
- Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial InfarctionNCT06854523 · not yet recruiting · started 2025
- Using OFR Software to Observe the Effects of Inclisiran Combined With Statins on the Morphology and Vascular Function of Coronary Vulnerable PlaquesNCT06338293 · recruiting · started 2024
The evidence so far
- Registered trials
- 27
- With posted results
- 4
- Published papers
- 0
Of 4 decided analyses: 0 favor pcsk9 inhibitors, 4 find no difference, 0 favor the comparator.
Trials
- Alirocumab in Patients With Acute Myocardial Infarction: A Randomized Controlled Double-Blinded StudyNCT02938949 · 2 posted results
- Evolocumab in Acute Coronary Syndrome: A Double-Blind Randomized Placebo Controlled StudyNCT03515304 · 4 posted results
- Evolocumab in Patients With Acute Myocardial Infarction: A Double-blind, Prospective, Randomized Placebo-Controlled StudyNCT04082442 · 1 posted result
- Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients: a Randomized Crossover TrialNCT06381947
- Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study with High-resolution MR Vessel Wall ImagingNCT05001984
- Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts With Acute Myocardial Infarction: A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Optical Coherence Tomography Imaging StudyNCT03067844
- PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary PreventionNCT07581808
- The Effects of Evolocumab on Endothelial and Inflammatory Biocellular Markers in Patients With Diabetes and Atherosclerotic Vascular Disease (METCHNIKOFF)NCT03829046 · 3 posted results